The global oncology hospital-to-home (H2H) drug administration market is forecast to grow at a 14.6% CAGR from 2025 to 2034 as care delivery shifts toward home-based treatment for cancer patients. The H2H model enables administration of therapies once confined to hospitals — including chemotherapy, immunotherapy, hormonal therapy and targeted agents — in patients’ homes with clinical oversight.
Home-based oncology care improves patient comfort, reduces infection risk, supports adherence to treatment schedules and helps patients maintain daily routines. For health systems, H2H programs relieve hospital capacity pressures, optimize resource use and can lower overall costs. Advances in home infusion equipment, tele-oncology, remote monitoring and specialized nursing services are strengthening the H2H ecosystem.
Market growth is driven by rising demand for patient-centric, convenient care; technological advances in infusion and monitoring; and pressure on providers and payers to adopt more efficient models amid rising healthcare costs. The need to reduce hospital crowding and infection exposure and the growing availability of skilled home-care oncology nurses also support adoption. Key constraints include the high cost of home-infusion technologies, stringent storage and handling requirements for oncology drugs, and uneven access to trained home-care oncology nurses.
The market spans multiple therapy types (immunotherapy, targeted therapies, maintenance chemotherapy, hormonal therapy and supportive and palliative infusions), service offerings (home infusion nursing, home chemotherapy, subcutaneous injection services, pharmacy compounding, care coordination, remote monitoring and drug-delivery logistics), provider models (home infusion companies, specialty pharmacies, integrated health-system programs and nurse workforce firms), reimbursement routes and patient settings from acute to palliative care.
Targeted therapies lead the H2H market because they are increasingly formulated for home delivery (oral agents, subcutaneous biologics and certain infusions), tend to be better tolerated than traditional chemotherapy and support personalized treatment approaches. Home infusion nursing is the fastest-growing service segment, providing the clinical expertise required for safe administration, monitoring and patient education and increasing confidence in home-based care.
North America currently leads the H2H market, supported by extensive home-health infrastructure, a skilled nursing workforce, reliable logistics and reimbursement frameworks that favor home care. The COVID-19 pandemic accelerated adoption as patients and providers sought safer alternatives to in-person hospital visits.
Leading companies active in the H2H oncology market include CareCentrix, Naven Health, Option Care Health, Onco360, Amerita, McKesson, Accredo, Amber Specialty Pharmacy, Sciensus, Lloyds Clinical (Lloyds Pharmacy Clinical Homecare), CarepathRx and BioScrip, among others.
Recent developments include Regeneron’s December 2025 announcement that odronextamab, a bispecific antibody combined with chemotherapy, produced a 100% complete response rate in a small trial of patients with diffuse large B-cell lymphoma, and a September 2025 report from BioNTech and Bristol Myers Squibb of early positive results for pumitamig combined with chemotherapy in advanced small-cell lung cancer; both updates are preliminary and require further study.
Market reports covering the sector provide revenue forecasts, company positioning, competitive analysis, growth prospects and regional and segment breakdowns for 2024–2034, with historical data from 2021–2023 and geographic scope including North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa.
Leave a Reply